CoChat

Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review

Open access

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past-year consumers. Dependence on amphetamines (AMPH) or methamphetamine (MA) is a growing global concern. Yet, there is no established pharmacotherapy for AMPH/MA dependence. A comprehensive assessment of the research literature on pharmacotherapy for AMPH/MA dependence may inform treatment guidelines and future research directions. METHODS: We systematically reviewed the peer-reviewed literature via the electronic databases PubMed, EMBASE, CINAHL and SCOPUS for randomised controlled trials reported in the English language examining a pharmacological treatment for AMPH/MA dependence or use disorder. We included all studies published to 19 June 2019. The selected studies were evaluated for design; methodology; inclusion and exclusion criteria; sample size; pharmacological and (if included) psychosocial interventions; length of follow-up and follow-up schedules; outcome variables and measures; results; overall conclusions and risk of bias. Outcome measures were any reported impact of treatment related to AMPH/MA use. RESULTS: Our search returned 43 studies that met our criteria, collectively enrolling 4065 participants and reporting on 23 individual pharmacotherapies, alone or in combination. Disparate outcomes and measures (n = 55 for the primary outcomes) across studies did not allow for meta-analyses. Some studies demonstrated mixed or weak positive signals (often in defined populations, e.g. men who have sex with men), with some variation in efficacy signals dependent on baseline frequency of AMPH/MA use. The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltrexone and topiramate. Less consistent benefits have been shown with the antidepressants bupropion and mirtazapine, the glutamatergic agent riluzole and the corticotropin releasing factor (CRF-1) antagonist pexacerfont; whilst in general, antidepressant medications (e.g. selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs]) have not been effective in reducing AMPH/MA use. CONCLUSIONS: No pharmacotherapy yielded convincing results for the treatment of AMPH/MA dependence; mostly studies were underpowered and had low treatment completion rates. However, there were positive signals from several agents that warrant further investigation in larger scale studies; agonist therapies show promise. Common outcome measures should include change in use days. Future research must address the heterogeneity of AMPH/MA dependence (e.g. coexisting conditions, severity of disorder, differences between MA and AMPH dependence) and the role of psychosocial intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-020-00711-x

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flow diagram
Fig. 1 PRISMA flow diagramCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Research works printed but not linked: 5

  1. World Health Organization. ICD-11: International classification of diseases for mortality and morbidity statistics: 11th rev. Geneva: World Health Organisation; 2018.
  2. United Nations Office on Drugs and Crime. Treatment of stimulant use disorder: Current practices and promising perspectives. Vienna: United Nations Office on Drugs and Crime; 2019.
  3. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org.
  4. Center for Behavioral Health Statistics and Quality. Results from the 2016 national survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2017.
  5. Australian Institute of Health and Welfare. National drug strategy household survey 2016: detailed findings. Canberra: Australian Institute of Health and Welfare; 2017.

Cited by

See all 194

Metadata

Authors
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N.
Affiliations
  • UNSW Sydney (AU)
  • St Vincent's Hospital Sydney (AU)
  • The University of Sydney (AU)
Corresponding author
Siefried, Krista J.
Venue
CNS Drugs
Published
2020-03-17
Volume
34
Issue
4
Pages
337-365
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3010839704
Cited by
194
References
84
Citations by year
2026: 17 · 2025: 42 · 2024: 32 · 2023: 29 · 2022: 38 · 2021: 31 · 2020: 5
FWCI
3.76
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Funders
Department of Health, Australian Government
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
methamphetamine dependence, amphetamine dependence, pharmacotherapy, d-amphetamine, methylphenidate, naltrexone, topiramate, bupropion, mirtazapine, riluzole, antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, men who have sex with men
MeSH terms
Amphetamine, Central Nervous System Stimulants, Animals, Humans, Methamphetamine, Substance-Related Disorders, Amphetamine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. https://app.cochat.ai/papers/10.1007/s40263-020-00711-x
The paper
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020). Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. CNS Drugs. https://doi.org/10.1007/s40263-020-00711-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.